US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
GlobeNewswire
*Ad hoc announcement pursuant to Art. 53 LR*
· TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension..